Motley Fool
0
All posts from Motley Fool
Motley Fool in Motley Fool,

Here's Why Clovis Oncology Inc. Jumped 70% in June

What happened

Clovis Oncology Inc. (NASDAQ: CLVS) stock soared 69.6% in June, according to data from S&P Global Market Intelligence. Clinical-trial results showed the company's lead drug Rubraca provided a significant long-term survival benefit.

So what 

Late last year, the Food and Drug Administration (FDA) granted Rubraca an accelerated approval for the treatment of a genetically defined group of ovarian-cancer patients, following treatment with two or more chemotherapies. The approval was based on the drug's ability to shrink tumors. Although the FDA is increasingly willing to speed potentially life-saving drugs to the market based on tumor shrinkage, such approvals are generally contingent upon their ability to prove a significant survival benefit over the long term.

Image source: Getty Images.

Rubraca is a member of a relatively new class of cancer therapies known as PARP inhibitors, and proof of a significant survival benefit should encourage more oncologists to add it to their treatment arsenals. The proof is pretty strong: According to an independent review, median progression-free survival among all patients treated with Rubraca was 13.7 months versus just 5.4 months among those given a placebo.

Now what

Clovis Oncology recorded just $7.0 million in Rubraca sales during its first full quarter post approval, and lost $58.5 million during the three-month period. Now that the company's sales force can tout compelling survival data, investors can reasonably expect a serious acceleration in sales of the drug and a less disturbing gap between sales and expenses this year.

Further ahead, the company intends to file another application to move Rubraca up a step in the ovarian-cancer treatment paradigm. At the moment, patients need to have been treated with two or more chemotherapies to become eligible for the drug.

A planned submission to expand its addressable patient population to patients with just one round of treatment could be a huge step on the company's path to profitability, if approved. Given the results announced last month, the company's chances of earning a label-expanding approval look pretty good.

10 stocks we like better than Clovis Oncology
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Clovis Oncology wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of June 5, 2017

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.